Syra Health Form 4 shows new 43,348-option grant to director

Rhea-AI Filing Summary

Syra Health Corp (SYRA) reported a new stock option grant to director Vijayapal R. Reddy. On 11/21/2025, he received stock options with an exercise price of $0.07 per share for 43,348 shares of Class A common stock, expiring on 11/21/2035.

The options were issued under the company’s 2022 Omnibus Equity Incentive Plan. One-third of the options vest on December 31, 2025, with the remaining two-thirds vesting in equal portions on December 31, 2026 and December 31, 2027. After this grant, Reddy beneficially owns 70,926 derivative securities (stock options).

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Reddy Vijayapal

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	43,348	$0.00	--

Holdings After Transaction: Stock Options — 70,926 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reddy Vijayapal

(Last) (First) (Middle)

C/O SYRA HEALTH CORP.

1119 KEYSTONE WAY N., #201

(Street)

CARMEL IN 46032

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Syra Health Corp [ SYRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$0.07	11/21/2025		A		43,348		(1)	11/21/2035	Class A Common Stock	43,348	$0	70,926	D

Explanation of Responses:

1. The options were issued pursuant to the Issuer's 2022 Omnibus Equity Incentive Plan.1/3 of the options vest on December 31, 2025 and the remainder vest in equal amounts on each of December 31, 2026 and 2027.

	/s/ Vijayapal R. Reddy	11/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity award was reported on this Syra Health (SYRA) Form 4?

The filing reports a grant of stock options to a Syra Health Corp director covering 43,348 shares of Class A common stock at an exercise price of $0.07 per share.

Who received the stock options in this Syra Health (SYRA) filing?

Director Vijayapal R. Reddy received the stock option grant reported, as indicated by the Form 4 showing his role as a Director and a single reporting person.

When do the new Syra Health (SYRA) stock options vest?

According to the filing, 1/3 of the options vest on December 31, 2025, and the remaining options vest in equal amounts on December 31, 2026 and December 31, 2027.

What is the expiration date of the director’s Syra Health (SYRA) stock options?

The stock options granted on 11/21/2025 have an expiration date of 11/21/2035, as shown in the derivative securities table.

How many derivative securities does the Syra Health (SYRA) director own after this transaction?

Following the reported transaction, the director beneficially owns 70,926 derivative securities (stock options), as disclosed in the Form 4.

Under which plan were the Syra Health (SYRA) options granted?

The options were issued under Syra Health Corp’s 2022 Omnibus Equity Incentive Plan, as stated in the Explanation of Responses.